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Abstract
Background Sarcopenia is a progressive age-related skeletal muscle disorder associated with increased likelihood of adverse
outcomes. Muscle wasting is often accompanied by an increase in body fat, leading to ‘sarcopenic obesity’. The aim of the
present study was to analyse the association of lifestyle variables such as diet, dietary components, physical activity (PA), body
composition, and inflammatory markers, with the risk of sarcopenic obesity.
Methods A cross-sectional analysis based on baseline data from the PREDIMED-Plus study was performed. A total of
1535 participants (48% women) with overweight/obesity (body mass index: 32.5 ± 3.3 kg/m2; age: 65.2 ± 4.9 years old)
and metabolic syndrome were categorized according to sex-specific tertiles (T) of the sarcopenic index (SI) as assessed
by dual-energy X-ray absorptiometry scanning. Anthropometrical measurements, biochemical markers, dietary intake,
and PA information were collected. Linear regression analyses were carried out to evaluate the association between
variables.
Results Subjects in the first SI tertile were older, less physically active, showed higher frequency of abdominal obesity and
diabetes, and consumed higher saturated fat and less vitamin C than subjects from the other two tertiles (all P < 0.05).
Multiple adjusted linear regression models evidenced significant positive associations across tertiles of SI with adherence to
the Mediterranean dietary score (P-trend < 0.05), PA (P-trend < 0.0001), and the 30 s chair stand test (P-trend < 0.0001),
whereas significant negative associations were found with an inadequate vitamin C consumption (P-trend < 0.05), visceral
fat and leucocyte count (all P-trend < 0.0001), and some white cell subtypes (neutrophils and monocytes), neutrophil-to-
lymphocyte ratio, and platelet count (all P-trend < 0.05). When models were additionally adjusted by potential mediators
(inflammatory markers, diabetes, and waist circumference), no relevant changes were observed, only dietary variables lost
significance.
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Conclusions Diet and PA are important regulatory mediators of systemic inflammation, which is directly involved in the
sarcopenic process. A healthy dietary pattern combined with exercise is a promising strategy to limit age-related
sarcopenia.
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Introduction
Sarcopenia is an age-associated process characterized by a
progressive loss of skeletal muscle mass and strength.1 This
condition is a major health concern in older adults because
it has been associated with metabolic impairments, cardio-
vascular disease risk factors, and physical and functional dis-
ability and increases the likelihood/risk of early mortality.2
All these metabolic and physical alterations cause important
healthcare costs and significantly affect quality of life.3
Sarcopenia often coexists with obesity leading to a specific
condition named ‘sarcopenic obesity’.4 Current evidences
suggest that sarcopenic obesity may be associated with a
larger number of metabolic disorders and an increased risk
of mortality than obesity or sarcopenia alone.5 However,
few studies have been carried out in this field and with con-
tradictory results. Cross-sectional studies in sarcopenic obe-
sity subjects have reported higher prevalence of
cardiovascular risk factors and metabolic syndrome in those
individuals.6,7 Strong associations with inflammatory markers
compared with sarcopenia-only subjects have been found.8
Conversely, some longitudinal studies have shown that
sarcopenic obesity does apparently not confer any greater
mortality risk than sarcopenia alone.9–11
There is evidence that the biological process of ageing is
characterized by oxidative stress and mitochondrial dysfunc-
tion.12 Increased reactive oxygen species production and
decreased antioxidant defences in older people seem to
be important factors contributing to muscle impairment.13
During ageing, in turn, chronic low-grade inflammation,
called inflammaging, develops, which contributes to the
pathogenesis of age-related diseases.14 Inflammaging has
been described as a common biological component of main
age-related chronic diseases such as atherosclerosis and
type 2 diabetes mellitus, and age-related conditions like
sarcopenia, frailty, and disability.15 Another new concept
that has emerged is ‘metaflammation’, the metabolic in-
flammation accompanying metabolic diseases driven by nu-
trient excess or overnutrition; metaflammation is
characterized by the same mechanisms underpinning
inflammaging. Lifestyle factors like diet and physical activity
(PA) are able to modulate oxidative and inflammatory pro-
cesses.16 Improving nutrition has been proposed as an ef-
fective strategy to reduce inflammaging and to prevent or
decelerate diet-related and age-related diseases.17,18 There-
fore, it could be hypothesized that lifestyle could play an
important role in the management and reversion of muscle
mass loss and promote a healthy body composition (BC). In
fact, PA (resistance training) in combination with proper nu-
trition (protein intake) is a promising strategy to limit age-
related sarcopenia.19 Nonetheless, little information is avail-
able comparing nutrient intake, BC, and lifestyle between
sarcopenic and non-sarcopenic obese older adults as well
as about the role of inflammatory processes associated with
sarcopenia. The aim of the present study was to analyse the
association of lifestyle variables such as diet, dietary compo-




The current research is a cross-sectional analysis including
baseline data of the PREDIMED-Plus study, a 6 year
multicentre, randomized, parallel-group, primary prevention
clinical trial conducted in Spain to assess the effect on cardio-
vascular disease morbi-mortality of a weight loss intervention
programme based on an energy-restricted traditional
Mediterranean diet, PA promotion, and behavioural support,
in comparison with a usual care intervention only with
energy-unrestricted Mediterranean diet (control group). A
more detailed description of the PREDIMED-Plus study has
been recently published,20 and there is available study infor-
mation at http://predimedplus.com/. This study was regis-
tered at the International Standard Randomized Controlled
Trial (http://www.isrctn.com/ISRCTN89898870) with Number
89898870 (registration date 24 July 2014).
Study subjects
A total of 6874 participants were recruited at 23 different
research sites in Spain and randomized to one of the two
study groups (September 2013–December 2016). The eligible
Journal of Cachexia, Sarcopenia and Muscle
DOI: 10.1002/jcsm.12442
Baseline data from the PREDIMED-Plus trial 975
2019; 10: 974–984
participants were community-dwelling adults (aged
65.2 ± 4.9 years) with overweight/obesity [body mass index
(BMI) = 32.5 ± 3.3 kg/m2], who met at least three compo-
nents of the metabolic syndrome according to the updated
harmonized criteria of the International Diabetes Federation
and the American Heart Association and National Heart,
Lung and Blood Institute.21 Information about exclusion
criteria has been previously published.20 Most of partici-
pants (97.5%) were of Caucasian origin. All participants
provided written informed consent, and the study protocol
and procedures were approved according to the ethical
standards of the Declaration of Helsinki by all the participat-
ing institutions.
The present work encompasses a subsample of partici-
pants who underwent dual-energy X-ray absorptiometry
(DXA) scans for BC assessment (n = 1535) in seven out of
the 23 PREDIMED-Plus recruiting centres, as these were the
only centres with available DXA scanner for this research.
Assessment of body composition with dual-energy
X-ray absorptiometry
Dual-energy X-ray absorptiometry scans (Lunar iDXA and DXA
Lunar Prodigy Primo, GE Healthcare) were performed by
trained radiology technicians to assess BC following a vali-
dated standardized protocol and subject positioning provided
by the manufacturer. The DXA was calibrated daily according
to manufacturer guidelines. Thus, total bone mass, fat mass,
lean mass, fat-free mass, and regionally distributed fat and
lean mass (trunk, android, gynoid, arms, and legs) were de-
termined. For visceral adipose tissue measures in the android
region, scans were reanalysed using validated CoreScan soft-
ware application.22 Appendicular skeletal muscle mass (ASM,
kg) was calculated as the sum of the muscle mass from the
four limbs as described elsewhere.23
Calculation of sarcopenic indexes
Skeletal muscle mass index (kg/m2) was calculated with the
equation ASM (kg)height2 (m). The sarcopenic index (SI)
was obtained by dividing the amount of ASM (kg) by the body
weight (kg) × 100.24 Participants were categorized according
to the sex-specific SI tertiles (women: T1: <21.0%, T2: ≥21.0
to <22.7%, and T3: ≥22.7; men: T1: <26.3%, T2: ≥26.3 to
<28.5%, and T3: ≥28.5%), which provide a good estimate of
the amount of skeletal muscle mass relative to body size.25
Thus, the higher index, the better for health.
Anthropometric, clinical, and biochemical variables
The anthropometric variables were measured at the base-
line visit by trained staff according to the PREDIMED-Plus
internal procedures. Body weight (kg) and height (cm) were
measured in light clothing and without shoes with the use
of a calibrated scale and a wall-mounted stadiometer,
respectively. BMI was calculated as weight (kg) divided by
the square of height (m). Waist circumference (cm) was
measured midway between the lowest rib and the iliac
crest using a measuring tape. Blood pressure and heart rate
were measured in triplicate with the use of a validated
semiautomatic oscillometer (Omron HEM-705CP, The
Netherlands) according to World Health Organization
criteria. Hypertensive participants were defined as those
that registered high blood pressure levels (≥130/85 mmHg)
at baseline or were on blood pressure medication.
Blood samples were collected at baseline after 12 h
overnight fast and were used to perform biochemical anal-
yses by means of standard laboratory enzymatic methods.
These analyses included plasma glucose (mg/dL), glycated
haemoglobin (HbA1c, %), high-density lipoprotein choles-
terol (HDL-c, mg/dL), and triglyceride (mg/dL) levels.
Current diabetes was defined as previous diagnosis of
diabetes or HbA1c ≥ 6.5%, use of antidiabetic medication,
or fasting glucose >126 mg/dL in the screening visit plus
fasting glucose >126 mg/dL at baseline visit. Participants
with low HDL-c concentration were those who had low
HDL-c levels, defined as <40 mg/dL in men and
<50 mg/dL in women, or with HDL-c medication at base-
line. Hypertriglyceridaemia was defined as presence of high
triglyceride levels (≥150 mg/dL) or triglyceride-lowering
drugs. A complete blood count was also performed follow-
ing standardized procedures. Blood parameters assessed in
this study were the white blood cell count, its subtypes
(lymphocytes, monocytes, neutrophils, and eosinophils),
and platelet count.
Dietary variables
At baseline, a trained dietitian administered a validated
143-item semi-quantitative food frequency questionnaire
to determine dietary factors in a face-to-face visit.26 Partic-
ipants were asked about their frequency consumption of
each specific item during the preceding year. There were
nine possible answers ranging from never to more than
six times per day, which were transformed to g/day, taking
into account the standard portion size of each item. Two
Spanish food composition tables were used to calculate
total energy and nutrients intake.27,28
The Mediterranean dietary pattern was calculated
according to a validated Mediterranean dietary score,29
considering the consumption of nine food groups or nutri-
ents (cereals, fruits and nuts, vegetables, legumes, fish,
meat, dairy products, ratio of monounsaturated to satu-
rated fatty acids, and alcohol).
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Physical activity variables
Leisure-time PA at baseline was evaluated with the validated
REGICOR questionnaire as detailed elsewhere,30 which in-
cluded questions about the activity type, frequency (number
of days), and duration (min/day) performed during a repre-
sentative month. As described previously,31 time spent in
PA (min/day) was further obtained by assigning to each activ-
ity their corresponding intensity according to the compen-
dium of PA.32,33 Time spent in total PA was computed as
the sum of the time from all PA intensities. The 30 s chair
stand test was used as an indicator of the lower-limb muscle
strength. As reported, performance was based on the num-
ber of times participants stand and sit in a chair in 30 s.34
Other sociodemographic variables
Participants self-reported baseline age, sex, smoking habit,
and educational level. Smoking was categorized as current,
former, and never smokers. Education was categorized as
bachelor’s degree, primary/secondary school, and no
education/no data.
Statistical analyses
Normality of variables was initially studied by using the
Shapiro–Wilk test. Baseline characteristics of the study
participants are presented as means ± standard deviation
for quantitative variables and numbers and percentages for
categorical variables. Differences in anthropometric, BC, and
biochemical variables, dietary characteristics, and food group
intake among the three SI sex-specific tertiles were tested by
analysis of variance and the χ2 test for categorical variables.
Multiple adjusted linear regression models were used to
evaluate the association between the variables showing a
strong relationship (in tertiles) with SI (as continuous vari-
able). We run first a minimally adjusted Model 1 including
sex, age, and centre (all exposures). Model 2 was adjusted
by the minimally sufficient adjustment set, determined using
directed acyclic graphs (DAGs) implemented in DAGitty soft-
ware,35 available free on www.dagitty.net. The DAGs were
built by identifying known factors affecting each of our expo-
sures on SI (see DAGs in Supporting Information, Figure S1A–
D). Thus, assuming the total effect of our exposures on SI, the
covariables used in Model 2 included sex, age, centre, PA (in
models with dietary, BC, and inflammatory variables as inde-
pendent variables), Mediterranean dietary score (in models
with PA, BC, and inflammatory variables as independent var-
iables), and waist circumference (in models with inflamma-
tory variables as independent variables).
Additionally, as sensitivity analyses, multivariable models
(Model 3) adjusted for the same covariables as in Model 2
plus mediators (direct effect determined using DAGs) were
run: diabetes, neutrophil-to-lymphocyte ratio (NLR) (in
models with dietary, PA, and BC variables as independent var-
iables), and waist circumference (in models with dietary and
PA variables as independent variables).
Lastly, we evaluated plausible effect modification by age
group (<65 or ≥65 years of age), sex, diabetes (yes/no), obe-
sity prevalence (BMI > 30 kg/m2), and centre, by adding an
interaction term between these variables and all exposures
in a multiple adjusted linear regression model (Model 2).
When a significant interaction was detected, stratified analy-
ses were conducted.
Statistical analyses were performed using Stata 12.0, and
the statistical significance was set at P < 0.05 for bilateral
contrast.
Results
Subjects were categorized according to SI sex-specific tertiles.
An overview on clinical and sociodemographic data, BC and
inflammatory markers, and dietary characteristics, consider-
ing SI tertiles, are given in Tables 1, 2, and 3, respectively.
Participants from the first SI tertile were on average older,
shorter, and had higher BMI, heart rate, and blood glucose
level than subjects from the upper two tertiles (all
P < 0.05) (Table 1). Subjects in the first SI tertile also showed
higher frequency of abdominal obesity and diabetes but
lower frequency of low HDL-c and hypertriglyceridaemia than
subjects from the upper two tertiles (all P < 0.05) (Table 1).
No differences in smoking habit and educational level were
observed among groups. On the other hand, significant
differences were found in PA among SI tertiles (P < 0.0001)
(Table 1). The 30 s chair test scoring was lower in participants
from the first tertile as compared with subjects from the
second and third tertiles (P < 0.0009) (Table 1).
Body composition variables showed no differences in bone
mass between groups. Subjects in the first tertile had higher
total fat mass, as well as higher trunk, android, gynoid, and
visceral fat content than subjects from the second and third
tertiles (all P < 0.0001) (Table 2). Regarding lean muscle
mass, subjects in the first SI tertile had lower total lean mass
and lower skeletal muscle mass index and fat-free mass
content than subjects from the other groups (all P < 0.001)
(Table 2).
No significant differences were observed in total energy
intake among SI tertiles. However, subjects from the first
tertile consumed less carbohydrate, fibre, and vitamin C and
more saturated fat, than subjects from the other two tertiles
(all P < 0.05) (Table 3). When dietary food groups were
assessed, main differences were observed in fruits, cereals,
and extra virgin olive oil, whose consumption was decreased
in participants with lower SI (all P < 0.05) (Table 3).
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Moreover, lower adherence to a validated Mediterranean di-
etary score was observed in the first tertile group as com-
pared with the second and third tertile participants
(P = 0.001) (Table 3).
Linear regression models were set up with SI as the
dependent variable and lifestyle variables such as diet, PA,
BC, and inflammatory markers as independent factors
(Table 4). Both minimally adjusted (Model 1) and multiple
adjusted (Model 2) models showed significant positive
associations between the lowest to highest tertile of SI and ad-
herence to the Mediterranean dietary score (P-trend = 0.045),
PA (P-trend < 0.0001), and the 30 s chair stand test (P-
trend < 0.0001), whereas significant negative associations
were found with an inadequate vitamin C consumption (P-
trend = 0.018), visceral fat (P-trend< 0.0001), leucocyte count
(P-trend< 0.0001), and some white cell subtypes [neutrophils
and monocytes (P-trend = 0.012)], NLR (P-trend = 0.010), and
platelet count (P-trend = 0.020). In Supporting Information,
Table S1 are shown other independent variables that were
significantly associated to SI in descriptive analyses. Carbo-
hydrates, fruits intake, and lean mass were significantly
and positively associated with SI (all P-trend < 0.05),
whereas saturated fat consumption, total fat, gynoid fat,
and eosinophil count were inversely associated with SI (all
P-trend ≤ 0.01). In order to estimate the magnitude of the
association explained by the interrelation between lifestyle,
obesity, inflammation, and sarcopenia, an additional Model
3 including all covariates to estimate the direct effect of
Table 1 Clinical and sociodemographic characteristics of the study participants according to sex-specific SI tertiles (T)
SI (%) P-value
T1 T2 T3
Men: 801 <26.3% ≥26.3 to <28.5% ≥28.5%
Women: 734 <21.0% ≥21.0 to <22.7% ≥22.7%
n = 1535 512 513 510 —
Men/women 267/245 268/245 266/244 —
Clinical variables
Age (years) 65.6 ± 5.0 65.3 ± 4.9 64.8 ± 5.0 0.036
Weight (kg) 90.2 ± 13.1 85.9 ± 12.6 82.8 ± 11.7 <0.0001
Height (cm) 162.0 ± 9.1 163.5 ± 9.5 163.6 ± 9.3 0.019
BMI (kg/m2) 34.2 ± 3.3 32.3 ± 3.0 30.8 ± 2.6 <0.0001
SBP (mmHg) 139.7 ± 16.9 140.1 ± 16.8 139.8 ± 16.8 0.940
DBP (mmHg) 79.9 ± 10.7 80.3 ± 9.8 80.3 ± 10.5 0.804
HR (b.p.m.) 70.9 ± 11.0 69.6 ± 10.8 67.6 ± 10.3 <0.0001
Glucose (mg/dL) 115.4 ± 32.6 112.1 ± 25.6 110.3 ± 23.9 0.010
Glycated haemoglobin (%) 6.10 ± 0.90 6.10 ± 0.70 6.00 ± 0.70 0.050
Metabolic syndrome criteria
Abdominal obesity, n (%) 504 (98) 480 (94) 455 (89) <0.0001*
Diabetes, n (%) 200 (39) 163 (32) 153 (30) 0.021*
Hypertension, n (%) 476 (93) 479 (93) 468 (92) 0.539*
Low HDL-c, n (%) 203 (40) 249 (49) 257 (50) 0.001*
Hypertriglyceridaemia, n (%) 251 (49) 298 (58) 313 (61) <0.0001*
Sociodemographic variables
Smoking habit, n (%)
Never 230 (45) 208 (41) 211 (41) 0.523*
Current 64 (12) 72 (14) 56 (11)
Former 218 (43) 231 (45) 243 (48)
Family history of obesity (%) 289 (57) 272 (53.2) 243 (48.0) 0.016*
Educational level, n (%)
Bachelor’s degree 104 (20) 113 (22) 110 (22) 0.930*
Primary/secondary 403 (79) 396 (77) 396 (77)
No education/no data 6 (1) 4 (1) 5 (1)
Physical activity (MET, min/day)
Inactive 329 (64) 274 (53) 245 (48) <0.0001*
Moderately active 85 (17) 100 (19) 130 (26)
Active 98 (19) 139 (27) 134 (26)
30 s chair test (repeats) 13.5 ± 5.1 14.3 ± 5.3 14.7 ± 5.2 0.0009
BMI, body mass index; DBP, diastolic blood pressure; HR, heart rate; HDL-c, high-density lipoprotein cholesterol; MET, metabolic equiva-
lent; SBP, systolic blood pressure; SI, sarcopenic index.
SI was calculated as a percentage of the total body weight: SI = [appendicular skeletal muscle mass (kg)weight (kg)] × 100. Data are pre-
sented as means ± standard deviations for quantitative variables and number and percentages for categorical variables. Differences in
characteristics among the three SI sex-specific tertiles were tested by analysis of variance. Metabolic syndrome criteria: abdominal obesity:
men: waist circumference ≥102 cm and women: waist circumference ≥88 cm; diabetes: fasting glucose ≥100 mg/dL or glycated
haemoglobin ≥6.5% or taking treatment; hypertension: SBP ≥ 135 mmHg or DBP ≥ 85 mmHg or taking antihypertensive medication;
low HDL-c levels: men ≤40 mg/dL and women ≤50 mg/dL or taking specific medication to regulate HDL-c; and hypertriglyceridaemia:
fasting triglyceride concentration ≥150 mg/dL or taking medication to regulate triglycerides.
*Categorical variables: the P-value was obtained by means of the χ2 test.
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Table 2 Body composition by DXA scanning and inflammatory markers of study participants according to SI sex-specific tertiles (T)
SI (%) P-value
T1 T2 T3
Men <26.3% ≥26.3 to <28.5% ≥28.5%
Women <21.0% ≥21.0 to <22.7% ≥22.7%
Body composition variables
Bone mass (kg) 2.6 ± 0.5 2.6 ± 0.5 2.6 ± 0.5 0.255
Total fat mass (%) 43.8 ± 6.0 40.3 ± 6.3 36.5 ± 6.5 <0.0001
Trunk fat (kg) 23.2 ± 4.3 20.1 ± 3.5 17.4 ± 2.9 <0.0001
Android fat (kg) 4.3 ± 0.9 3.6 ± 0.7 3.1 ± 0.6 <0.0001
Gynoid fat (kg) 5.7 ± 1.4 5.0 ± 1.3 4.2 ± 1.0 <0.0001
VAT (kg) 2.6 ± 0.9 2.3 ± 0.8 2.0 ± 0.6 <0.0001
Total lean mass (%) 53.1 ± 5.8 56.5 ± 6.0 60.1 ± 6.2 <0.0001
SMI (kg/m2) 7.6 ± 1.0 8.0 ± 1.1 8.4 ± 1.1 <0.0001
FFM (kg) 49.8 ± 9.8 50.8 ± 10.3 52.2 ± 10.6 0.0008
Inflammatory markers
WBC (× 109/L) 6.9 ± 1.8 6.8 ± 2.0 6.5 ± 3.2 0.043
Lymphocytes 2.5 ± 3.5 2.6 ± 3.8 2.4 ± 3.3 0.844
Monocytes 0.6 ± 0.7 0.5 ± 0.7 0.5 ± 0.7 0.908
Neutrophils 4.8 ± 6.7 4.5 ± 6.3 4.2 ± 6.3 0.434
Eosinophils 0.2 ± 0.4 0.2 ± 0.2 0.2 ± 0.2 0.236
NLR 2.2 ± 3.4 2.0 ± 1.6 1.8 ± 1.6 0.072
Platelet count (× 109/L) 230 ± 57 227 ± 54 226 ± 57 0.440
DXA, dual-energy X-ray absorptiometry; FFM, fat-free mass; NLR, neutrophil-to-lymphocyte ratio; VAT, visceral adipose tissue; SI,
sarcopenic index; SMI, skeletal muscle mass index; WBC, white blood cell count.
Differences in characteristics among the three SI sex-specific tertiles were tested by analysis of variance.
Table 3 Dietary consumption of study participants according to SI sex-specific tertiles (T)
SI (%) P-value
T1 T2 T3
Men: 803 <26.3% ≥26.3 to <28.5% ≥28.5%
Women: 734 <21.0% ≥21.0 to <22.7% ≥22.7%
Nutrients
Energy intake (kcal/day) 2402 ± 582 2389 ± 576 2443 ± 589 0.293
Carbohydrates (%) 39.6 ± 6.4 40.0 ± 6.7 40.9 ± 6.2 0.003
Proteins (%) 16.4 ± 2.6 16.4 ± 2.7 16.1 ± 2.4 0.094
Lipids (%) 40.6 ± 6.1 40.2 ± 6.2 39.7 ± 5.8 0.052
PUFA (%) 6.2 ± 1.8 6.3 ± 1.8 6.2 ± 1.7 0.553
SFA (%) 10.3 ± 1.9 10.0 ± 1.9 9.8 ± 1.9 0.0001
MUFA (%) 21.3 ± 4.5 21.0 ± 4.3 20.8 ± 4.0 0.238
Fibre (g/day) 25.2 ± 8.3 25.4 ± 9.0 26.8 ± 8.2 0.003
Alcohol intake (g/day) 11.6 ± 15.2 11.8 ± 15.5 11.7 ± 15.1 0.974
ω3 fatty acids (g/day) 0.85 ± 0.44 0.86 ± 0.45 0.88 ± 0.46 0.578
Fish ω3 fatty acids (g/day) 0.63 ± 0.33 0.63 ± 0.35 0.66 ± 0.36 0.312
Vitamin C (mg/day) 194 ± 81 202 ± 89 209 ± 84 0.016
Vitamin D (μg/day) 5.8 ± 3.1 5.8 ± 3.2 6.0 ± 3.3 0.610
Food groups
Vegetables (g/day) 300 ± 116 308 ± 127 318 ± 122 0.054
Fruits (g/day) 321 ± 193 328 ± 192 366 ± 206 0.0004
Legumes (g/day) 20.0 ± 11.4 19.6 ± 10.4 19.5 ± 9.6 0.686
Cereals (g/day) 146 ± 79 153 ± 84 163 ± 83 0.004
Dairy products (g/day) 345 ± 215 336 ± 206 329 ± 193 0.418
Meats (g/day) 157 ± 59 155 ± 61 149 ± 56 0.087
Extra virgin olive oil (g/day) 31.5 ± 21.0 33.9 ± 19.9 34.6 ± 19.8 0.038
Fish (g/day) 95.9 ± 42.3 95.8 ± 45.2 101 ± 47 0.150
Nuts (g/day) 14.0 ± 17.9 14.2 ± 16.0 14.9 ± 17.1 0.649
Confectionery (g/day) 26.5 ± 33.5 26.3 ± 28.5 28.1 ± 34.1 0.606
Mediterranean diet score (points) 4.2 ± 1.5 4.3 ± 1.6 4.5 ± 1.6 0.001
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; SI, sarcopenic index.
Differences in characteristics among the three SI sex-specific tertiles were tested by analysis of variance.
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each exposure on SI, independently of potential mediators
(Table 4 and Supporting Information, Table S1), was per-
formed. Overall, no relevant changes were detected, that
is, associations that were significant in Model 2 remained
significant in Model 3. The association of some dietary expo-
sures, that is, Mediterranean diet score, carbohydrates, and
fruits intake, became weaker after adjusting for diabetes,
obesity, and inflammation.
Table 4 Linear regression models with SI as the dependent variable and lifestyle, body composition, and inflammatory variables as independent
factors




T1 Ref Ref Ref
T2 0.02 (–0.25; 0.30) 0.01 (0.27; 0.26) 0.14 (0.39; 0.09)
T3 0.39 (0.09; 0.69) 0.32 (0.02; 0.62) 0.16 (0.10; 0.42)
P-trend 0.015 0.045 0.340
Vitamin C (mg/day) ≥RDA Ref Ref Ref
<RDA 0.65 (1.18; 0.11) 0.55 (1.09; 0.02) 0.64 (1.12; 0.16)




Inactive Ref Ref Ref
Moderately
active
0.84 (0.55; 1.14) 0.82 (0.52; 1.11) 0.48 (0.21; 0.75)
Active 1.11 (0.79; 1.43) 1.08 (0.76; 1.41) 0.59 (0.29; 0.89)
P-trend <0.0001 <0.0001 <0.0001
30 s chair test (repeats) T1 Ref Ref Ref
T2 0.49 (0.21; 0.77) 0.49 (0.21; 0.76) 0.24 (0.01; 0.49)
T3 1.04 (0.72; 1.36) 1.02 (0.70; 1.35) 0.55 (0.25; 0.84)
P-trend <0.0001 <0.0001 <0.0001
Body composition variables
Android fat (g) T1 Ref Ref Ref
T2 1.45 (1.69; 1.21) 1.43 (1.67; 1.19) 1.42 (1.66; 1.18)
T3 2.91 (3.15; 2.67) 2.85 (3.10; 2.61) 2.83 (3.07; 2.58)
P-trend <0.0001 <0.0001 <0.0001
Visceral adipose tissue (g) T1 Ref Ref Ref
T2 0.72 (1.14; 0.30) 0.70 (1.07; 0.33) 0.68 (1.05; 0.30)
T3 1.88 (2.30; 1.46) 1.81 (2.19; 1.44) 1.81 (2.19; 1.43)
P-trend <0.0001 <0.0001 <0.0001
Inflammatory variables
Leucocyte count (× 109/L) T1 Ref Ref Ref
T2 0.21 (0.49; 0.05) 0.26 (0.51; 0.01) 0.22 (0.47; 0.02)
T3 0.69 (0.97; 0.41) 0.45 (0.71; 0.20) 0.45 (0.70; 0.20)
P-trend <0.0001 <0.0001 0.001
Neutrophil count (× 109/L) T1 Ref Ref Ref
T2 0.31 (0.59; 0.03) 0.24 (0.49; 0.007) 0.22 (0.47; 0.02)
T3 0.75 (1.03; 0.48) 0.48 (0.73; 0.23) 0.45 (0.70; 0.20)
P-trend <0.0001 0.012 <0.0001
Monocyte count (× 109/L) T1 Ref Ref Ref
T2 0.38 (0.66; 0.10) 0.26 (0.51; 0.009) 0.23 (0.49; 0.01)
T3 0.59 (0.88; 0.30) 0.32 (0.59; 0.06) 0.29 (0.55; 0.02)
P-trend <0.0001 0.012 0.026
NLR T1 Ref Ref Ref
T2 0.0006 (0.27; 0.27) 0.08 (0.16; 0.33) 0.08 (0.16; 0.33)
T3 0.52 (0.80; 0.23) 0.33 (0.58; 0.08) 0.31 (0.57; 0.06)
P-trend <0.0001 0.010 0.015
Platelet count (× 109/L) T1 Ref Ref Ref
T2 0.06 (0.34; 0.21) 0.13 (0.38; 0.11) 0.13 (0.38; 0.11)
T3 0.36 (0.64; 0.08) 0.30 (0.55; 0.04) 0.28 (0.53; 0.30)
P-trend 0.012 0.020 0.028
CI, confidence interval; MET, metabolic equivalent; NLR, neutrophil-to-lymphocyte ratio; RDA, recommended dietary allowances; SI,
sarcopenic index.
RDA for vitamin C (90 mg/day for men and 75 mg/day for women). Analyses were performed using multivariable linear regression models.
Model 1: adjusted by centre, sex, and age; Model 2: Model 1 additionally adjusted for plausible confounders: physical activity (in models
with dietary, body composition, and inflammatory variables as independent variables), Mediterranean dietary score (in models with phys-
ical activity, body composition, and inflammatory variables as independent variables), and waist circumference (in models with inflamma-
tory variables as independent variables); and Model 3 (sensitivity analyses): Model 2 additionally adjusted by plausible mediators:
diabetes, NLR (in models with dietary, physical activity, and body composition variables as independent variables), and waist circumfer-
ence (in models with dietary and physical activity variables as independent variables).
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Effect modification analyses revealed a significant interac-
tion between sex and PA, android fat, neutrophil, and platelet
count on SI (all P for interaction <0.05). However, analyses
stratified by sex showed that only the association between
platelet count and SI was significant in men (P-trend = 0.002)
but not in women (P-trend = 0.687). Also, the association
between NLR and SI was only statistically evident in diabetics
(P-trend = 0.027, P for interaction = 0.029) (Supporting Infor-
mation, Table S2). Centre heterogeneity was observed in the
association between the android fat, 30 s chair test, leucocyte
count, and NLR with SI (all P < 0.05) (Supporting Information,
Figure S2A–D).
Discussion
The aim of the present study was to analyse the association
of lifestyle variables such as diet, dietary components, PA,
BC, and inflammatory markers, with the risk of sarcopenia.
Most relevant results show that diet, the adherence to a die-
tary pattern such as Mediterranean diet as well as some die-
tary components like vitamin C and saturated fat, and PA are
associated with sarcopenia, while obesity, particularly ab-
dominal obesity, some metabolic alterations such as diabe-
tes, and inflammatory factors seem to be mediating the
effect. Both diet and PA have a direct impact on the develop-
ment of obesity and metabolic alterations. This effect might
be mediated mainly through the regulation of the inflamma-
tory state as observed in the regression Model 3 when poten-
tial mediators were included. The association of diet with the
SI lost the significance when the model was additionally ad-
justed by waist circumference, NLR, and diabetes, which sug-
gests that obesity, inflammation, and diabetes are strong
mediators of the effect of diet on SI. Interestingly, some spe-
cific dietary components such as vitamin C and saturated fat
remained significant after adjusting by these potential media-
tors. Vitamin C and saturated fat consumption could have a di-
rect effect on the process of sarcopenia. Some authors suggest
that micronutrient intake, specifically vitamin C, is inadequate
in obese subjects and subjects with metabolic syndrome.36,37
An inadequate intake of vitamin C contributes to small over-
growth, transcytosis of enteric bacteria, and an elevation of li-
popolysaccharides, which elicits a low-grade inflammatory
response.37 On the other hand, saturated fat can activate
transmembrane proteins (toll-like receptors 2 and 4) involved
in the activation of the innate immune system, leading to the
activation of proinflammatory pathways and the secretion of
proinflammatory cytokines, which predispose to adipose tis-
sue inflammation and subsequent insulin resistance.38
The sarcopenia condition of the study participants could
be assumed as a chronic condition considering that all sub-
jects of the study were overweight or obese and had met-
abolic syndrome. Chronic sarcopenia is likely to be
associated with permanent and progressive processes such
as ageing, obesity, and metabolic syndrome.1,39 It is not
established which condition develops first, and due to the
cross-sectional nature of the study, it is not possible to de-
termine the cause and consequence. Sarcopenia and obe-
sity are considered as the multifactorial syndromes with
various overlapping causes and feedback mechanisms sup-
posed to be strongly interconnected and aggravate each
other.40 On the other hand, the natural process of ageing
is associated with an increase in visceral fat and a progres-
sive loss of muscle mass driven by a low-grade chronic in-
flammation also referred as ‘inflammaging’.14 The excess
of android and visceral fat promotes inflammation leading
to a low-grade chronic inflammatory state that is involved
in the obesity-related metabolic alterations as well as in
the process of sarcopenia. Participants in the study had a
leucocyte count within the clinical range; however, the
slight and clinically insignificant increase in leucocytes ob-
served in subjects from tertile 1 might be accelerating the
sarcopenic process. An accelerated or decelerated ageing will
depend on the individual genetic background interacting life-
long with environmental and lifestyle factors (nutrition, phys-
ical, mental activity, etc.).14 The metabolic pathways involved
in sarcopenia and sarcopenic obesity are poorly understood.
However, available scientific evidences support the role of in-
flammation on the process of sarcopenia, which seem to be
mediated through alterations on glucose metabolism such as
hyperglycaemia and insulin resistance.8,41 Insulin resistance
often occurs with abdominal obesity, and the association be-
tween both conditions is influenced by an overproduction of
inflammatory cytokines.42,43 Hyperglycaemia, insulin resis-
tance, and excess cytokine production have been shown to im-
pact sarcopenia by promoting the deterioration of skeletal
muscle fibre diameter and protein content, as well as
prompting metabolic breakdown of skeletal muscle encourag-
ing sarcopenic process.44 In the present study, a significant in-
teraction between NLR and diabetes on the SI was featured.
The stratified analysis (diabetics and no diabetics) showed that
the association of NLR with the SI was significant only in dia-
betic participants according to the theory that insulin resis-
tance and inflammation impact on the sarcopenia process.
Several sex interactions were found with PA, android fat,
and neutrophil and platelet counts on SI. In the stratified
analysis of the data by sex, the association of these exposures
was not different between men and women, simply was
stronger in men than in women. Men have more appendicu-
lar skeletal muscle mass, and the PA could be more effective
in men than in women. On the other hand, android fat mass
content used to be greater in men than in women. Therefore,
inflammatory markers as well as android fat mass content
were more strongly associated to SI in men than in women.
Centre interactions were also observed with the 30 s chair
test, android fat, mass content, leucocyte count, and NLR
on the risk of SI. It is important to mention that despite the
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establishment of a standardized protocol and the great
efforts of all the groups involved in the project to follow it
correctly, it has finally been inevitable to obtain some
heterogeneity between centres. Accordingly, we repeated
the analyses stratifying by centre. Some centres showed
higher spread data, but the associations were in the same
direction. In any case, care should be taken concerning the
overall interpretation of the data.
Some limitations should be mentioned concerning this
investigation, because it is a cross-sectional design and
causal effects cannot be inferred, and although regression
models were adjusted for many variables, residual confound-
ing is still possible. Depending on the sarcopenic obesity
definition, there are more or less subjects with sarcopenic
obesity, which indicates that some definitions could be
underestimating/overestimating sarcopenia. Nutritional in-
formation and PA data come from self-reported question-
naires, and in spite that FFQ and PA questionnaires have
been previously validated, this information should be treated
with caution.
Conclusions
The present research investigated main differences in BC, bio-
chemical, and lifestyle variables among pre-obese and obese
older adults with metabolic syndrome and different SI values,
trying to find out risk factors potentially involved in the onset
and development of sarcopenia/sarcopenic obesity. Impor-
tant differences were observed in BC, biochemical, and life-
style factors being android/visceral adipose tissue, leucocyte
and platelet counts, and NLR strong risk factors for the SI,
while adherence to the Mediterranean diet, the intake of
some specific nutrients (such as vitamin C), and PA appeared
as protective factors for the development of sarcopenia.
Improving nutrition and regular PA are key factors for decel-
erating the sarcopenic process and assure a healthy ageing.
Actions to develop successful intervention programmes for
a healthy lifestyle in order to promote a quality ageing
focused on muscle mass maintenance, prevention of obesity,
and independence living are warranted.
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